Introduction: In this study, the effects of the cannabinoid CBD were assessed on cyclooxygenase (COX)-1 and COX-2 expression and activity in resting and activated human neutrophils (polymorphonuclear [PMN] leukocytes).Methods: COX expression was measured at the mRNA levels, whereas COX activity was assessed by enzyme-linked immunosorbent assay measurement of prostaglandin (PG)E-2. In vitro experiments in a standard commercial acellular assay of COX-1/COX-2 activity completed the study.Results: Results show that CBD profoundly inhibits expression of COX-1 and COX-2 mRNA in activated PMN, however, without any significant consequences for PGE(2) production. CBD, however, was able to induce a slight but significant direct inhibition of COX-2 in the acellular model.Conclusion: The effects of CBD occur in the mu M concentration range, which is attained in humans with therapeutic doses of the drug, suggesting the clinical relevance of these findings.

Effect of Cannabidiol on Cyclooxygenase Type 1 and 2 Expression and Function in Human Neutrophils

Cosentino, Marco;Legnaro, Massimiliano;Luini, Alessandra;Ferrari, Marco;Marino, Franca
2022-01-01

Abstract

Introduction: In this study, the effects of the cannabinoid CBD were assessed on cyclooxygenase (COX)-1 and COX-2 expression and activity in resting and activated human neutrophils (polymorphonuclear [PMN] leukocytes).Methods: COX expression was measured at the mRNA levels, whereas COX activity was assessed by enzyme-linked immunosorbent assay measurement of prostaglandin (PG)E-2. In vitro experiments in a standard commercial acellular assay of COX-1/COX-2 activity completed the study.Results: Results show that CBD profoundly inhibits expression of COX-1 and COX-2 mRNA in activated PMN, however, without any significant consequences for PGE(2) production. CBD, however, was able to induce a slight but significant direct inhibition of COX-2 in the acellular model.Conclusion: The effects of CBD occur in the mu M concentration range, which is attained in humans with therapeutic doses of the drug, suggesting the clinical relevance of these findings.
2022
2022
COX-1; COX-2; PGE2; PMN; cannabidiol
Cosentino, Marco; Legnaro, Massimiliano; Luini, Alessandra; Ferrari, Marco; Sodergren, Mikael; Pacchetti, Barbara; Marino, Franca
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2147071
 Attenzione

L'Ateneo sottopone a validazione solo i file PDF allegati

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact